Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.

H&E and GD2 IHC were performed on post-treatment biopsies at SA pathology ( figure 6A ; left column H&E, right column GD2 staining in dark red), and an automated analysis of GD2 staining intensity and tumor-infiltrating lymphocytes (TILs), which was performed by an independent pathologist, showed a trend toward decreased GD2 staining post-treatment (p=0.053) and no difference in the level of TIL (p=0.7) ( online supplemental figure S9A,B ).

also in 53,322 other papers